Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25078976,bioavailability,"Bioequivalence criteria for comparison of pregabalin CR after a low- or medium-calorie breakfast relative to pregabalin IR were not met; however, bioavailability of the pregabalin CR vs. IR formulation was relatively high (75-86 %).","Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078976/),%,75-86,1893,DB00230,Pregabalin
,19845930,Area under the curve from time 0 to 36 hours,The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),[h·μg] / [ml],81.8,12210,DB00230,Pregabalin
,19845930,absorption half-life,The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),h,0.38,12211,DB00230,Pregabalin
,19845930,elimination half-life,The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),h,6.90,12212,DB00230,Pregabalin
,19845930,time over,The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),[μg] / [ml],2.8,12213,DB00230,Pregabalin
,19845930,minimal effective concentration,The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),h,11.11,12214,DB00230,Pregabalin
,19845930,maximal plasma concentration (C(max)),The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),[μg] / [ml],7.15,12215,DB00230,Pregabalin
,19845930,time for,The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),h,1.5,12216,DB00230,Pregabalin
,19845930,C(max) to occur,The median (range) pharmacokinetic parameters were: Area under the curve from time 0 to 36 hours = 81.8 (56.5-92.1) microg hour mL(-1); absorption half-life = 0.38 (0.25-1.11) hours; elimination half-life = 6.90 (6.21-7.40) hours; time over 2.8 microg mL(-1) (the presumed minimal effective concentration) = 11.11 (6.97-14.47) hours; maximal plasma concentration (C(max)) = 7.15 (4.6-7.9) microg mL(-1); time for C(max) to occur = 1.5 (1.0-4.0) hours.,Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),h,1.5,12217,DB00230,Pregabalin
,19845930,minimal,"Assuming an 8-hour dosing interval, predicted minimal, average, and maximal steady state plasma concentrations were 6.5 (4.8-8.1), 8.8 (7.3-10.9), and 13.0 (8.8-15.2) microg mL(-1).",Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),[μg] / [ml],6.5,12218,DB00230,Pregabalin
,19845930,maximal steady state plasma concentrations,"Assuming an 8-hour dosing interval, predicted minimal, average, and maximal steady state plasma concentrations were 6.5 (4.8-8.1), 8.8 (7.3-10.9), and 13.0 (8.8-15.2) microg mL(-1).",Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),[μg] / [ml],8.8,12219,DB00230,Pregabalin
,19845930,maximal steady state plasma concentrations,"Assuming an 8-hour dosing interval, predicted minimal, average, and maximal steady state plasma concentrations were 6.5 (4.8-8.1), 8.8 (7.3-10.9), and 13.0 (8.8-15.2) microg mL(-1).",Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845930/),[μg] / [ml],13.0,12220,DB00230,Pregabalin
,16337109,ED50,"In the high-intensity electroshock test, pregabalin potently inhibited tonic extensor seizures in rats (ED50 = 1.8 mg/kg, PO), and low-intensity electroshock seizures in mice.",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],1.8,16032,DB00230,Pregabalin
,16337109,ED50,"It prevented tonic extensor seizures in the DBA/2 audiogenic mouse model (ED50 = 2.7 mg/kg, PO).",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],2.7,16033,DB00230,Pregabalin
,16337109,ED50 1,"At higher dosages (ED50 1= 31 mg/kg, PO), pregabalin prevented clonic seizures from pentylenetetrazole in mice.",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],31,16034,DB00230,Pregabalin
,31415852,drug,The drug entrapment efficiency was 74.33 ± 0.04% to 89.63 ± 0.01% and swelling of microspheres followed the pattern (blended >coated >plain).,Taro-corms mucilage-alginate microspheres for the sustained release of pregabalin: In vitro &in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31415852/),%,74.33,28246,DB00230,Pregabalin
,31415852,entrapment efficiency,The drug entrapment efficiency was 74.33 ± 0.04% to 89.63 ± 0.01% and swelling of microspheres followed the pattern (blended >coated >plain).,Taro-corms mucilage-alginate microspheres for the sustained release of pregabalin: In vitro &in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31415852/),%,74.33,28247,DB00230,Pregabalin
,31415852,entrapment efficiency,The drug entrapment efficiency was 74.33 ± 0.04% to 89.63 ± 0.01% and swelling of microspheres followed the pattern (blended >coated >plain).,Taro-corms mucilage-alginate microspheres for the sustained release of pregabalin: In vitro &in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31415852/),%,89.63,28248,DB00230,Pregabalin
,20147618,oral bioavailability,Pregabalin oral bioavailability is approximately 90% and is independent of dose and frequency of administration.,Clinical pharmacokinetics of pregabalin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20147618/),%,90,36254,DB00230,Pregabalin
,20147618,elimination half-life,Pregabalin elimination half-life is approximately 6 hours and steady state is achieved within 1 to 2 days of repeated administration.,Clinical pharmacokinetics of pregabalin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20147618/),h,6,36255,DB00230,Pregabalin
,11554426,influx (CLin),"BBB influx (CLin) and efflux (CLout) permeability for pregabalin were 4.8 and 37.2 microL/min/g brain, respectively, following an intravenous infusion to rats.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),[μl] / [brain·g·min],4.8,54621,DB00230,Pregabalin
,11554426,efflux (CLout) permeability,"BBB influx (CLin) and efflux (CLout) permeability for pregabalin were 4.8 and 37.2 microL/min/g brain, respectively, following an intravenous infusion to rats.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),[μl] / [brain·g·min],37.2,54622,DB00230,Pregabalin
,11554426,ECe50,"The resulting Ce (concentration in effect compartment) versus effect profile exhibits a sigmoidal curve and the calculated ECe50 and Keo values were 95.3 ng/mL and 0.0092 min-1, respectively.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),[ng] / [ml],95.3,54623,DB00230,Pregabalin
,11554426,Keo,"The resulting Ce (concentration in effect compartment) versus effect profile exhibits a sigmoidal curve and the calculated ECe50 and Keo values were 95.3 ng/mL and 0.0092 min-1, respectively.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),1/[min],0.0092,54624,DB00230,Pregabalin
,29874779,elimination half-life time (t1/2),"Our results showed that the blood concentration of TTX reached a maximum plasma concentration (Cmax) at around 2 h, with an elimination half-life time (t1/2) of 3.23 ± 1.74 h after intragastric administration.",Effect of Tetrodotoxin Pellets in a Rat Model of Postherpetic Neuralgia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29874779/),h,3.23,54783,DB00230,Pregabalin
,29874779,lethal dose (LD50),"The median lethal dose (LD50) of TTX pellets was 517.43 μg/kg via oral administration to rats, while the median effective dose (ED50) was approximately 5.85 μg/kg, and the therapeutic index was 88.45.",Effect of Tetrodotoxin Pellets in a Rat Model of Postherpetic Neuralgia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29874779/),[μg] / [kg],517.43,54784,DB00230,Pregabalin
,29874779,effective dose (ED50),"The median lethal dose (LD50) of TTX pellets was 517.43 μg/kg via oral administration to rats, while the median effective dose (ED50) was approximately 5.85 μg/kg, and the therapeutic index was 88.45.",Effect of Tetrodotoxin Pellets in a Rat Model of Postherpetic Neuralgia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29874779/),[μg] / [kg],5.85,54785,DB00230,Pregabalin
,32099329,time of the peak plasma concentration,The time of the peak plasma concentration at 6 h in the fed state of humans coincided with the results of the study on beagles.,Development of a Novel Controlled-Release Tablet of Pregabalin: Formulation Variation and Pharmacokinetics in Dogs and Humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32099329/),h,6,68938,DB00230,Pregabalin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00230,Pregabalin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00230,Pregabalin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00230,Pregabalin
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00230,Pregabalin
,23357837,Cmax,"Mean Cmax and AUC0-∞ for the capsule were within 2% of those for the solution (3.8 vs. 3.7 μg/ml and 26.7 vs. 27.0 μg×h/ml, respectively).","Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357837/),[μg] / [ml],3.8,81012,DB00230,Pregabalin
,23357837,Cmax,"Mean Cmax and AUC0-∞ for the capsule were within 2% of those for the solution (3.8 vs. 3.7 μg/ml and 26.7 vs. 27.0 μg×h/ml, respectively).","Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357837/),[μg] / [ml],3.7,81013,DB00230,Pregabalin
,23357837,AUC0-∞,"Mean Cmax and AUC0-∞ for the capsule were within 2% of those for the solution (3.8 vs. 3.7 μg/ml and 26.7 vs. 27.0 μg×h/ml, respectively).","Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357837/),[h·μg] / [ml],26.7,81014,DB00230,Pregabalin
,23357837,AUC0-∞,"Mean Cmax and AUC0-∞ for the capsule were within 2% of those for the solution (3.8 vs. 3.7 μg/ml and 26.7 vs. 27.0 μg×h/ml, respectively).","Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357837/),[h·μg] / [ml],27.0,81015,DB00230,Pregabalin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,160.2,83468,DB00230,Pregabalin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,55.1,83469,DB00230,Pregabalin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,172.2,83470,DB00230,Pregabalin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,95.,83471,DB00230,Pregabalin
,27443664,C<sub>max</sub>,"The mean C<sub>max</sub> values for test and reference were 4.290 and 4.164 µg/mL, and the mean AUC<sub>0-last</sub> values were 24.275 h×µg/mL and 23.674 h×µg/mL, respectively.",Bioequivalence assessment of two pregabalin capsules in healthy Mediterranean Arab volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443664/),[μg] / [ml],4.290,95522,DB00230,Pregabalin
,27443664,C<sub>max</sub>,"The mean C<sub>max</sub> values for test and reference were 4.290 and 4.164 µg/mL, and the mean AUC<sub>0-last</sub> values were 24.275 h×µg/mL and 23.674 h×µg/mL, respectively.",Bioequivalence assessment of two pregabalin capsules in healthy Mediterranean Arab volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443664/),[μg] / [ml],4.164,95523,DB00230,Pregabalin
,27443664,AUC<sub>0-last</sub>,"The mean C<sub>max</sub> values for test and reference were 4.290 and 4.164 µg/mL, and the mean AUC<sub>0-last</sub> values were 24.275 h×µg/mL and 23.674 h×µg/mL, respectively.",Bioequivalence assessment of two pregabalin capsules in healthy Mediterranean Arab volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443664/),[h·μg] / [ml],24.275,95524,DB00230,Pregabalin
,27443664,AUC<sub>0-last</sub>,"The mean C<sub>max</sub> values for test and reference were 4.290 and 4.164 µg/mL, and the mean AUC<sub>0-last</sub> values were 24.275 h×µg/mL and 23.674 h×µg/mL, respectively.",Bioequivalence assessment of two pregabalin capsules in healthy Mediterranean Arab volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27443664/),[h·μg] / [ml],23.674,95525,DB00230,Pregabalin
,30079339,peak pregabalin concentration,The peak pregabalin concentration was 8.3 ± 1.6 μg/ml which occurred at 2.9 ± 1.2 h.,Pharmacokinetics of Single-Dose Oral Pregabalin Administration in Normal Cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079339/),[μg] / [ml],8.3,102929,DB00230,Pregabalin
,30079339,Elimination half-life,Elimination half-life was 10.4 ± 2.6 h and area under the curve was 133.9 ± 71.5 μg-h/ml.,Pharmacokinetics of Single-Dose Oral Pregabalin Administration in Normal Cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079339/),h,10.4,102930,DB00230,Pregabalin
,30079339,area under the curve,Elimination half-life was 10.4 ± 2.6 h and area under the curve was 133.9 ± 71.5 μg-h/ml.,Pharmacokinetics of Single-Dose Oral Pregabalin Administration in Normal Cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079339/),[μg-h] / [ml],133.9,102931,DB00230,Pregabalin
,30079339,Time above the minimum therapeutic concentration,Time above the minimum therapeutic concentration for seizure control in dogs and people (2.8 μg/ml) was 17.6 ± 6.2 h.,Pharmacokinetics of Single-Dose Oral Pregabalin Administration in Normal Cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079339/),[μg] / [ml],2.8,102932,DB00230,Pregabalin
,30079339,Time above the minimum therapeutic concentration,Time above the minimum therapeutic concentration for seizure control in dogs and people (2.8 μg/ml) was 17.6 ± 6.2 h.,Pharmacokinetics of Single-Dose Oral Pregabalin Administration in Normal Cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079339/),h,17.6,102933,DB00230,Pregabalin
,29878981,mobile phase flow rate,"PGB-d4 was used as internal standard, and the chromatographic separations were performed on Poroshell 120 EC-C18 column using an isocratic mobile phase flow rate of 1 mL/min.",An Improved LC-ESI-MS/MS Method to Quantify Pregabalin in Human Plasma and Dry Plasma Spot for Therapeutic Monitoring and Pharmacokinetic Applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29878981/),[ml] / [min],1,104838,DB00230,Pregabalin
,23891703,Volume of distribution,Volume of distribution of TPM was estimated at 0.575 l/kg.,Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [kg],0.575,116785,DB00230,Pregabalin
,23891703,CL/F,"Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ.",Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [h],2.46,116786,DB00230,Pregabalin
,29649518,relative bioavailability,"Compared with conventional capsules, the relative bioavailability of gastro-floating tablet in fasted conditions or in fed conditions was only 62.47 ± 10.80% and 100.98 ± 17.25% respectively, even though the gastro-floating tablet obtained decreased Cmax and prolonged Tmax in fasted and fed conditions.",Design and optimization of gastro-floating sustained-release tablet of pregabalin: In vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29649518/),%,62.47,121867,DB00230,Pregabalin
,29649518,relative bioavailability,"Compared with conventional capsules, the relative bioavailability of gastro-floating tablet in fasted conditions or in fed conditions was only 62.47 ± 10.80% and 100.98 ± 17.25% respectively, even though the gastro-floating tablet obtained decreased Cmax and prolonged Tmax in fasted and fed conditions.",Design and optimization of gastro-floating sustained-release tablet of pregabalin: In vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29649518/),%,100.98,121868,DB00230,Pregabalin
,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,50-400,122850,DB00230,Pregabalin
>,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,"15,000",122851,DB00230,Pregabalin
≤,21036913,minimal effective dose,KLYP961 also attenuated capsaicin-induced thermal allodynia in rhesus primates in a dose-related manner with a minimal effective dose (≤ 10 mg/kg p.o.) and a greater potency than gabapentin.,"Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),mg,10,122852,DB00230,Pregabalin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,1.97,130205,DB00230,Pregabalin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,1.6,130206,DB00230,Pregabalin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,0.27,130207,DB00230,Pregabalin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,0.3,130208,DB00230,Pregabalin
,26961752,Renal clearance,Renal clearance averaged 68.2 mL/min.,"The Pharmacokinetics of Pregabalin in Breast Milk, Plasma, and Urine of Healthy Postpartum Women. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961752/),[ml] / [min],68.2,138433,DB00230,Pregabalin
,20975469,time to peak pregabalin concentration,The median time to peak pregabalin concentration in CSF was at 8 hrs.,Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975469/),h,8,140129,DB00230,Pregabalin
,22716224,Time to maximum observed plasma concentration (T(max) ),Time to maximum observed plasma concentration (T(max) ) was 1.53 (95% CI 1.09-2.05).,The absorption profile of pregabalin in chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22716224/),,1.53,141472,DB00230,Pregabalin
,22716224,maximum plasma concentration (C(max) ),"The maximum plasma concentration (C(max) ) was 1.98 μg/ml (95% CI 1.69-2.34), and area under the plasma concentration-time profile (area under the curve) was 18.2 μg*hr/ml (95% CI 14.7-26.3).",The absorption profile of pregabalin in chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22716224/),[μg] / [ml],1.98,141473,DB00230,Pregabalin
,22716224,area under the plasma concentration-time profile (area under the curve),"The maximum plasma concentration (C(max) ) was 1.98 μg/ml (95% CI 1.69-2.34), and area under the plasma concentration-time profile (area under the curve) was 18.2 μg*hr/ml (95% CI 14.7-26.3).",The absorption profile of pregabalin in chronic pancreatitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22716224/),[h·μg] / [ml],18.2,141474,DB00230,Pregabalin
,24311644,Retention rates,"Retention rates were 59% in the LEV group, and 41% in the PGB group.",Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24311644/),%,59,146841,DB00230,Pregabalin
,24311644,Retention rates,"Retention rates were 59% in the LEV group, and 41% in the PGB group.",Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24311644/),%,41,146842,DB00230,Pregabalin
,24726707,serum concentration,The mean serum concentration of LPP1 measured 30 min following i.p. administration was 7904.6 ± 1066.1 ng/ml.,Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726707/),[ng] / [ml],7904.6,155372,DB00230,Pregabalin
,17144644,bioavailable,"Pregabalin is rapidly absorbed with at least 90% bioavailable irrespective of dose, does not bind to plasma proteins and is excreted virtually unchanged by the kidneys.",[Pregabalin (Lyrica) and neuropathic pain syndromes]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144644/),%,90,159783,DB00230,Pregabalin
,23318283,Urinary elimination half-lives,Urinary elimination half-lives based upon creatinine-normalized concentrations were 5.7-5.9 hours.,Detection times of pregabalin in urine after illicit use: when should a positive specimen be considered a new intake? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318283/),h,5.7-5.9,168527,DB00230,Pregabalin
,23318283,urinary elimination half-life,"By applying a urinary elimination half-life of 6 hours on that material, at least 50% would be expected to have negative urine specimens within 3 days and a total of 5 days would be needed to achieve negative urine specimens in the subject with the maximum urinary concentration measured.",Detection times of pregabalin in urine after illicit use: when should a positive specimen be considered a new intake? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318283/),h,6,168528,DB00230,Pregabalin
,23251735,C(max),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.10,171096,DB00230,Pregabalin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.10,171097,DB00230,Pregabalin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],10.35,171098,DB00230,Pregabalin
,23251735,AUC(0-∞),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],13.92,171099,DB00230,Pregabalin
,23251735,C(max),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.15,171100,DB00230,Pregabalin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.15,171101,DB00230,Pregabalin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],10.31,171102,DB00230,Pregabalin
,23251735,AUC(0-∞),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],13.78,171103,DB00230,Pregabalin
,28513426,t<sub>max</sub>,"Pharmacokinetic parameters were determined that test and reference products showed 0.96 ± 0.35 and 1.04 ± 0.96 hours for t<sub>max</sub>, 4,594.217 ± 834.195 and 4,568.68 ± 573.963 ng/mL for C<sub>max</sub>, 30,048.150 ± 2,998.920 and 29,315.722 ± 2,747.396 ng×h/mL for AUC<sub>0-t</sub>, 30,594.210 ± 2,872.317 and 29,831.454 ± 2,688.020 ng×h/mL for AUC<sub>0-inf</sub>, respectively.",Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513426/),h,1.04,181621,DB00230,Pregabalin
,28513426,AUC<sub>0-t</sub>,"Pharmacokinetic parameters were determined that test and reference products showed 0.96 ± 0.35 and 1.04 ± 0.96 hours for t<sub>max</sub>, 4,594.217 ± 834.195 and 4,568.68 ± 573.963 ng/mL for C<sub>max</sub>, 30,048.150 ± 2,998.920 and 29,315.722 ± 2,747.396 ng×h/mL for AUC<sub>0-t</sub>, 30,594.210 ± 2,872.317 and 29,831.454 ± 2,688.020 ng×h/mL for AUC<sub>0-inf</sub>, respectively.",Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513426/),[h·ng] / [ml],"30,048.150",181622,DB00230,Pregabalin
,28513426,AUC<sub>0-t</sub>,"Pharmacokinetic parameters were determined that test and reference products showed 0.96 ± 0.35 and 1.04 ± 0.96 hours for t<sub>max</sub>, 4,594.217 ± 834.195 and 4,568.68 ± 573.963 ng/mL for C<sub>max</sub>, 30,048.150 ± 2,998.920 and 29,315.722 ± 2,747.396 ng×h/mL for AUC<sub>0-t</sub>, 30,594.210 ± 2,872.317 and 29,831.454 ± 2,688.020 ng×h/mL for AUC<sub>0-inf</sub>, respectively.",Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513426/),[h·ng] / [ml],"29,315.722",181623,DB00230,Pregabalin
,28513426,AUC<sub>0-inf,"Pharmacokinetic parameters were determined that test and reference products showed 0.96 ± 0.35 and 1.04 ± 0.96 hours for t<sub>max</sub>, 4,594.217 ± 834.195 and 4,568.68 ± 573.963 ng/mL for C<sub>max</sub>, 30,048.150 ± 2,998.920 and 29,315.722 ± 2,747.396 ng×h/mL for AUC<sub>0-t</sub>, 30,594.210 ± 2,872.317 and 29,831.454 ± 2,688.020 ng×h/mL for AUC<sub>0-inf</sub>, respectively.",Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513426/),[h·ng] / [ml],"30,594.210",181624,DB00230,Pregabalin
,28513426,AUC<sub>0-inf,"Pharmacokinetic parameters were determined that test and reference products showed 0.96 ± 0.35 and 1.04 ± 0.96 hours for t<sub>max</sub>, 4,594.217 ± 834.195 and 4,568.68 ± 573.963 ng/mL for C<sub>max</sub>, 30,048.150 ± 2,998.920 and 29,315.722 ± 2,747.396 ng×h/mL for AUC<sub>0-t</sub>, 30,594.210 ± 2,872.317 and 29,831.454 ± 2,688.020 ng×h/mL for AUC<sub>0-inf</sub>, respectively.",Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28513426/),[h·ng] / [ml],"29,831.454",181625,DB00230,Pregabalin
,16234874,oral bioavailability,Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%.,Pregabalin: a new agent for the treatment of neuropathic pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16234874/),%,90,181695,DB00230,Pregabalin
,16234874,plasma half-life,"Pregabalin is not protein-bound and exhibits a plasma half-life of about 6 hours, which is not dose-dependent.",Pregabalin: a new agent for the treatment of neuropathic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16234874/),h,6,181696,DB00230,Pregabalin
,25078977,Relative bioavailability,"Relative bioavailability of pregabalin CR was 93-97 % of pregabalin IR, and bioequivalence criteria with respect to the 24-h steady-state exposure (area under the plasma concentration-time curve from 0 to 24 h [AUC24]) were met.",Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078977/),%,93-97,193632,DB00230,Pregabalin
,25078977,relative bioavailability,"The relative bioavailability of two-tablet pregabalin CR was 97-102 % of one-tablet pregabalin CR, and bioequivalence criteria with respect to AUC24 and peak plasma concentrations were met.",Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078977/),%,97-102,193633,DB00230,Pregabalin
,25945069,AUC0-t,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),[h·ng] / [ml],"27,845.86",197996,DB00230,Pregabalin
,25945069,AUC0-∞,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),[h·ng] / [ml],"28,311.70",197997,DB00230,Pregabalin
,25945069,Cmax,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),[h·ng] / [ml],"28,311.70",197998,DB00230,Pregabalin
,25945069,t1/2,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),h,5.66,197999,DB00230,Pregabalin
,25945069,AUC0-t,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),[h·ng] / [ml],"27,398.12",198000,DB00230,Pregabalin
,25945069,AUC0-∞,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),[h·ng] / [ml],"27,904.24",198001,DB00230,Pregabalin
,25945069,Cmax,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),[h·ng] / [ml],"27,904.24",198002,DB00230,Pregabalin
,25945069,t1/2,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),[ng] / [ml],"3,849.50",198003,DB00230,Pregabalin
,25945069,t1/2,"The mean (standard deviation [SD]) AUC0-t, AUC0-∞, Cmax, and t1/2 of pregabalin from the test formulation were 27,845.86 (4,508.27) ng · h/mL, 28,311.70 (4,790.55) ng · h/mL, 3,999.71 (801.52) ng/mL, and 5.66 (1.20) hours, respectively; while the mean (SD) AUC0-t, AUC0-∞,Cmax, and t1/2 of pregabalin from the reference formulation were 27,398.12 (4,266.28) ng · h/mL, 27,904.24 (4,507.31) ng · h/mL, 3,849.50 (814.50) ng/mL, and 5.87 (1.25) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),h,5.87,198004,DB00230,Pregabalin
,25945069,tmax,"The median (range) tmax of pregabalin from the test formulation and reference formulation was 1.00 (0.67-2.00) hours and 1.00 (0.67-3.00) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),h,1.00,198005,DB00230,Pregabalin
,25945069,tmax,"The median (range) tmax of pregabalin from the test formulation and reference formulation was 1.00 (0.67-2.00) hours and 1.00 (0.67-3.00) hours, respectively.",Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25945069/),h,1.00,198006,DB00230,Pregabalin
,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,60,209278,DB00230,Pregabalin
,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,33,209279,DB00230,Pregabalin
> or =,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,90,209280,DB00230,Pregabalin
,20818832,elimination half-lives,"Both drugs are excreted renally, with elimination half-lives of approximately 6 hours.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),h,6,209281,DB00230,Pregabalin
,17940637,elimination half-life,It has a mean elimination half-life of 6.3 hours.,"Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17940637/),h,6.3,244022,DB00230,Pregabalin
,24574633,terminal elimination half-life,The calculated terminal elimination half-life was 11.5 h.,Pregabalin-associated myoclonic encephalopathy without evidence of drug accumulation in a patient with acute renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24574633/),h,11.5,249092,DB00230,Pregabalin
,23802677,maximal plasma concentration,"After intragastric administration, median (range) maximal plasma concentration was 5.0 μg/mL (4.4 to 6.7 μg/mL), time to maximal plasma concentration was 1.",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),[μg] / [ml],5.0,266311,DB00230,Pregabalin
,23802677,time to maximal plasma concentration,"After intragastric administration, median (range) maximal plasma concentration was 5.0 μg/mL (4.4 to 6.7 μg/mL), time to maximal plasma concentration was 1.",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),,1,266312,DB00230,Pregabalin
,23802677,elimination half-life,"0 hour (0.5 to 2.0 hours), elimination half-life was 8.0 hours (6.2 to 9.4 hours), and area under the curve from time 0 to infinity (AUC0-∞) was 47.2 μg·h/mL (36.4 to 58.4 μg·h/mL).",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),h,8.0,266313,DB00230,Pregabalin
,23802677,area under the curve from time 0 to infinity (AUC0-∞),"0 hour (0.5 to 2.0 hours), elimination half-life was 8.0 hours (6.2 to 9.4 hours), and area under the curve from time 0 to infinity (AUC0-∞) was 47.2 μg·h/mL (36.4 to 58.4 μg·h/mL).",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),[h·μg] / [ml],47.2,266314,DB00230,Pregabalin
,23802677,initial concentration,"After IV administration, initial concentration was 22.2 μg/mL (19.8 to 27.7 μg/mL), elimination half-life was 7.74 hours (6.94 to 8.17 hours), and AUC0-∞ was 48.3 μg·h/mL (44.8 to 57.2 μg·h/mL).",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),[μg] / [ml],22.2,266315,DB00230,Pregabalin
,23802677,elimination half-life,"After IV administration, initial concentration was 22.2 μg/mL (19.8 to 27.7 μg/mL), elimination half-life was 7.74 hours (6.94 to 8.17 hours), and AUC0-∞ was 48.3 μg·h/mL (44.8 to 57.2 μg·h/mL).",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),h,7.74,266316,DB00230,Pregabalin
,23802677,AUC0-∞,"After IV administration, initial concentration was 22.2 μg/mL (19.8 to 27.7 μg/mL), elimination half-life was 7.74 hours (6.94 to 8.17 hours), and AUC0-∞ was 48.3 μg·h/mL (44.8 to 57.2 μg·h/mL).",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),[h·μg] / [ml],48.3,266317,DB00230,Pregabalin
,23802677,Bioavailability,Bioavailability was 97.7% (80.7% to 109.8%).,Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),%,97.7,266318,DB00230,Pregabalin
,23802677,minimal,"Median predicted values for minimal, mean, and maximal steady-state plasma concentrations after intragastric administration assuming an 8-hour dosing interval were 3.9, 5.3, and 6.3 μg/mL, respectively.",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),[μg] / [ml],3.9,266319,DB00230,Pregabalin
,23802677,mean,"Median predicted values for minimal, mean, and maximal steady-state plasma concentrations after intragastric administration assuming an 8-hour dosing interval were 3.9, 5.3, and 6.3 μg/mL, respectively.",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),[μg] / [ml],5.3,266320,DB00230,Pregabalin
,23802677,maximal steady-state plasma concentrations,"Median predicted values for minimal, mean, and maximal steady-state plasma concentrations after intragastric administration assuming an 8-hour dosing interval were 3.9, 5.3, and 6.3 μg/mL, respectively.",Pharmacokinetics of single-dose intragastric and intravenous pregabalin administration in clinically normal horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802677/),[μg] / [ml],6.3,266321,DB00230,Pregabalin
,28025964,AUC<sub>last</sub>,"The extent of exposure in terms of AUC<sub>last</sub> amounted to 26,018.3 - 3,580.8 µg×h/L for the test formulation and 25,680.2 ± 3,083.6 µg×h/L for the reference formulation.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[h·μg] / [l],"26,018.3 - 3,580.8",267899,DB00230,Pregabalin
,28025964,AUC<sub>last</sub>,"The extent of exposure in terms of AUC<sub>last</sub> amounted to 26,018.3 - 3,580.8 µg×h/L for the test formulation and 25,680.2 ± 3,083.6 µg×h/L for the reference formulation.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[h·μg] / [l],"25,680.2",267900,DB00230,Pregabalin
,28025964,C<sub>max</sub>,"C<sub>max</sub> reached values of 4,782.7 ± 1,124.2 µg/L and 4,654.0 ± 911.4 µg/L for the test product and reference product, respectively.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[μg] / [l],"4,782.7",267901,DB00230,Pregabalin
,28025964,C<sub>max</sub>,"C<sub>max</sub> reached values of 4,782.7 ± 1,124.2 µg/L and 4,654.0 ± 911.4 µg/L for the test product and reference product, respectively.",Bioequivalence of two formulations of pregabalin 150-mg capsules under fasting conditions in healthy male subjects . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025964/),[μg] / [l],"4,654.0",267902,DB00230,Pregabalin
